QBP1 Peptide as a Potential Anti-Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Area of Science:

• Biochemistry
• Molecular Biology
• Diabetes Research

Background:

• Human islet amyloid polypeptide (hIAPP) aggregation into amyloid fibrils is linked to pancreatic beta-cell failure and type 2 diabetes (T2D).
• Developing inhibitors to disrupt hIAPP amyloidogenesis is a therapeutic strategy for T2D.

Purpose of the Study:

• To evaluate the anti-amyloidogenic peptide QBP1's efficacy in preventing hIAPP aggregation and cytotoxicity.
• To assess QBP1's cytoprotective effects on pancreatic beta cells under amyloidogenic stress.

Main Methods:

• Cell-free aggregation assays (Thioflavin-T, dot blotting, electron microscopy).
• Spectroscopic analyses (circular dichroism, NMR) to study hIAPP conformational changes.
• Cell-based assays (viability, immunocytochemistry, gene expression) using Antp-QBP1 in INS-1E cells.
• In silico molecular dynamics simulations to elucidate QBP1-hIAPP interactions.

Main Results:

• QBP1 significantly inhibited hIAPP β-sheet formation and oligomerization in vitro, comparable to epigallocatechin-3-gallate.
• Antp-QBP1 protected INS-1E beta cells from amyloidogenic stress, preserving viability and homeostasis.
• Molecular dynamics simulations revealed stable QBP1-hIAPP interactions via non-polar and aromatic residue contacts.

Conclusions:

• QBP1 is a potent inhibitor of hIAPP amyloidogenesis and associated beta-cell toxicity.
• QBP1 demonstrates potential as a therapeutic agent for reducing islet amyloid burden in T2D.
• QBP1 preserves beta-cell integrity, offering a promising strategy for T2D management.